Shionogi &
4507.TPharmaceutical
Filed as Shionogi & Co., Ltd. (2022-06–2026-09)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥499.7bn | ¥438.3bn | ¥410.1bn | ¥426.7bn | ¥335.1bn | ¥297.2bn |
| Operating income | ¥166.7bn | ¥156.6bn | ¥153.3bn | ¥149.0bn | ¥110.3bn | ¥117.4bn |
| Net income (owners) | ¥205.2bn | ¥170.4bn | ¥162.0bn | ¥185.0bn | ¥114.2bn | ¥111.9bn |
| Total assets | ¥2.58T | ¥1.54T | ¥1.42T | ¥1.31T | ¥1.15T | ¥999.0bn |
| Net assets / equity | ¥1.69T | ¥1.36T | ¥1.25T | ¥1.12T | ¥993.3bn | ¥864.5bn |
| Operating cash flow | ¥213.6bn | ¥195.5bn | ¥154.3bn | ¥177.9bn | ¥102.1bn | ¥109.0bn |
| EPS (basic) | ¥241.11 | ¥200.36 | ¥186.17r | ¥207.1r | ¥126.25r | ¥121.68r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 211 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 211 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 82 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 211 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 226 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 106 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 241 figures · EDINET |
| 2020-04-01 → 2021-03-31 | AnnualAmended | 247 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 106 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 247 figures · EDINET |
21 more reports are still being processed.